Navigation Links
Access Pharmaceuticals Presents New Data at International Symposium Showing Company's Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells
Date:6/26/2008

DALLAS, June 26 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced that the Company gave an oral presentation yesterday on its monoclonal antibody product, Angiolix(R), at the 7th International Congress on Recombinant Antibodies, held in Dublin, Ireland. Dr. Agamemnon Epenetos, Access' Chief Scientific Officer -- Europe, presented data showing that Angiolix has the potential to prevent the growth of cancer stem cells.

Dr. Epenetos commented, "There is a growing body of evidence that indicates that tumor progression, dissemination and metastases result from cancer stem cells rather than the other cells which form the bulk of a cancer. As a result, therapies which attack these tumor cells will delay the onset of progression, but rarely cure the disease. Cancer stem cells are a subgroup of cancer cells that can be resistant to standard treatments, so agents like Angiolix, which have the potential to thwart cancer stem cells, hold great promise for the future treatment and eradication of cancer."

Access' monoclonal antibody product, Angiolix, blocks angiogenesis by inhibiting a novel receptor called lactadherin. Lactadherin causes angiogenesis through a VEGF dependent mechanism. Several other drugs have been developed or are in development to block VEGF and VEGF induced angiogenesis, such as Avastin.

In the presentation, Dr. Epenetos showed that Angiolix has been shown not only to block new blood vessels in tumors, in a similar manner to other anti VEGF drugs like Avastin, but that it could additionally have a direct killing effect on tumor cells potentially including cancer stem cells that are involved in angiogenesis and metastasis.

Access Pharmaceuticals is currently conducting key preclinical studies at Imperial College London, UK to assess the efficacy of Angiolix in a wide range of tumor models. These studies aim to demonstrate the potential efficacy of Angiolix as a monotherapy and in com
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
2. A Perfect Storm Threatens Patient Access to Specialty Medical Care
3. AMT Makes Important Advance in the Development of its Gene Therapy for Hemophilia B -Company Accesses Technology to Prevent Immune Response
4. Access Licenses ProLindac(TM) to Jiangsu Aosaikang Pharmaceutical Co., LTD., a Leading Oncology Pharmaceutical Company for Manufacturing, Development and Commercialization in the Greater China Region
5. HistoRx Announces Expanded Access of AQUA(R) Technology to 900+ Researchers at Dana-Farber/Harvard Cancer Center
6. AMT Accesses Technology for Treatment of Duchenne Muscular Dystrophy
7. Access Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. SurgiQuest Announces First Single Port Procedure for Ovary Removal Using AirSeal(TM) Access System
9. Scientists call for more access to biotech crop data
10. Perceptive Informatics Improves Clinical Site Monitoring Access and Flexibility With Portable USB Drive Capability
11. Canadian Centre for DNA Barcoding to Participate in Microchip Biotechnologies Early Access Program for Microchip-Based DNA Sample Preparation and Cycle Sequencing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... , Feb. 26, 2015  NuGene International, ... aesthetic products for skin and hair rejuvenation, has ... as agency of record for investor relations and ... improve our distribution, sales and diversification strategies – ... current and prospective shareholders," stated Ali Kharazmi CEO ...
(Date:2/26/2015)... The Pittcon 2015 Exposition, which takes ... Morial Convention Center in New Orleans, Louisiana, will ... 2015) displaying products and services used by the ... The Exposition will offer the latest innovations in ... chemistry; drug discovery; nanotechnology; life sciences to include ...
(Date:2/26/2015)... February 26, 2015 RURO, Inc., a ... FreezerPro® version 6.2 – the latest update to the ... is that of a quick and easy method to ... the latest version, RURO engineering has enhanced the system’s ... move large amounts of sample records. , "FreezerPro ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 Regis Technologies ... the development of oncology drug substances. , Regis Technologies ... of their new Potent Compound Suite (PCS) for 2015. ... 36,000 square foot, cGMP facility in Morton Grove, Illinois. ... manufacturing of potent compounds up to about one kilogram ...
Breaking Biology Technology:NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3Pittcon 2015 Announces Exposition Highlights 2RURO Releases FreezerPro® version 6.2 2Regis Extends cGMP Services to Oncology Market 2
... 5 Bionovo, Inc.,(Nasdaq: BNVI ), a leader in ... areas of women,s health and cancer, today announced,that Tom Chesterman, ... 4th,Annual BIO Investor Forum. The presentation will take place ... Hotel in San Francisco, CA. A live audio web ...
... Wyeth,Pharmaceuticals, a division of Wyeth (NYSE: ... a definitive agreement under which it has ... Aberdeen that is focused on the discovery,of ... robust biotechnology drug discovery capabilities. "Haptogen ...
... Lexicon,Pharmaceuticals, Inc. (Nasdaq: LXRX ) today announced that ... officer, will present,at the BIO InvestorForum at The Palace ... at 11:00 a.m. Pacific Time. A live webcast ... at http://www.lexpharma.com . An archived version of the,webcast ...
Cached Biology Technology:Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery 2Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery 3Lexicon Pharmaceuticals to Present at Bio InvestorForum 2
(Date:1/22/2015)... , January 22, 2015 , ... year  The European Patent Office to present a video ... British nominations to be featured: Christofer Toumazou and ... former finalists and winners of the Award   Starting ...
(Date:1/22/2015)... , Jan. 22, 2015   EyeLock, Inc. , a ... has appointed Steve Gerber to the new role ... be responsible for leading development of mobile platforms and wearable ... of success and innovation in the semiconductor industry to his ...
(Date:12/24/2014)... YORK , Dec. 23, 2014  Since its launch in December ... people to eliminate the pain of trying to remember their ... own biometrics fused to their smartphones. To assist people who ... , the company that created 1U and focuses on redefining ...
Breaking Biology News(10 mins):Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3
... gene that produces a mutant form of good ... than therapy using the "normal" HDL gene, according ... at Cedars-Sinai Medical Center and reported in the ... American College of Cardiology. , Apolipoprotein A-I is ...
... a three-dimensional ultrasound scanner they developed can successfully guide ... in various medical settings, according to the researchers. They ... performed without surgeons, a capability that could prove valuable ... "It's the first time, to our knowledge, that anyone ...
... we hate. And yet, our "taste" for certain flavors and foods ... tired of eating the same old thing. , Now, a ... on in the brain when we taste something we like, or ... although the study used rats instead of people, it has direct ...
Cached Biology News:Gene transfer using mutant form of good cholesterol cuts vascular plaque and inflammation 2Gene transfer using mutant form of good cholesterol cuts vascular plaque and inflammation 33-D ultrasound scanner could guide robotic surgeries 23-D ultrasound scanner could guide robotic surgeries 3Tastes great! Study shows brain's response to pleasing -- and changing -- tastes 2Tastes great! Study shows brain's response to pleasing -- and changing -- tastes 3
...
Small bottle for hybridization 150 x 35mm...
Extra Large bottle for hybridization 300 x 70mm...
... Multidrop Combi is a new generation dispenser combining ... with the proven performance of the existing Multidrop ... large volume area starting from 500 nl up ... range. ,It is optimized for multiple ...
Biology Products: